Non-small cell lung cancer (NSCLC) is a malignant tumour with quite high cancer specific mortality, and it still lacks stable and reliable markers for NSCLC's prognosis. Platelet derived grow factor (PDGF) and PDGFR has been considered to be involved in the process of cell proliferation, migration, metastasis and epithelial mesenchymal transition of cancer cell through various intracellular signal pathways. Pathology analysis showed that PDGF pathway mainly stimulates the proliferation of NSCLC tumour stroma through paracrine pattern, and some reaseach found that PDGF pathway directly promotes some NSCLC cell's proliferation. The expression of PDGF and PDGFR within NSCLC tissue correlates with status of lymphatic metastasis and patients' prognosis. In clinical treatment of NSCLC, the great effect of PDGF pathway in angiogenesis and promoting distribution of chemotherapy by inhibition of PDGF should not be neglected. As an important pro-angiogenesis pathway, functions of PDGF in radiotherapy is dicovered by more and more fundamental research. This review focuses on the progress of PDGF pathway in NSCLC and aims to provide some new ideas for clinical and fundamental researchers.
非小细胞肺癌（non-small cell lung cancer, NSCLC）作为全球癌症相关死亡率较高的恶性肿瘤，目前仍缺少可靠稳定的预后指标。血小板源生长因子（platelet derived grow factor, PDGF）及其受体通过多种细胞内信号通路参与细胞生长，迁移，转移以及上皮间叶转化等过程。病理结果表明，PDGF通路主要通过旁分泌途径刺激NSCLC肿瘤间质生长，亦有发现PDGF通路对某些NSCLC肿瘤细胞可能存在直接驱动作用。NSCLC组织中的PDGF及其受体的表达与肿瘤的预后，淋巴结转移等临床结果相关。在临床治疗中，PDGF通路对NSCLC血管生成的重要作用，及抑制PDGF通路促进化疗药物在实体瘤内部分布的作用不容忽视。PDGF作为重要的促血管生成通路，在NSCLC放射治疗中的作用也越来越多地被各种基础研究证实。本文拟对PDGF通路在NSCLC领域的研究进展做一综述，以求对临床和基础研究者有一些启发。